Note that whereas these three examples occur recurrently across melanoma or liver cancer (for TERT) or across T-cell acute lymphoblastic leukemia (for TAL1 and LMO1), they represent exceptional cases, since whole-genome sequencing, even across large cohorts such as 560 breast cancer genomes [7], failed to identify additional binding site changes that are significantly recurrent [8] (recently reviewed in [9–11]). This evidence concerns the gene TAL1 and melanoma.